- Email: [email protected]
MP13-13 FUNCTIONAL RESULTS AFTER PHOTOVAPORISATION OF THE PROSTATE (PVP) WITH GREENLIGHT XPS LASER: A PROSPECTIVE MULTI-INSTITUTIONAL STUDY.
THE JOURNAL OF UROLOGYâ
Vol. 193, No. 4S, Supplement, Friday, May 15, 2015
e141
was 50 ml in each age group and not different among them (p>0.05). The overall morbidity rates were similar among the age groups (28.3%, 36.6%, 32.9%, p>0.05), as were the incidence of significant complications (Clavien two or larger) and median loss of haemoglobin (1.1 g/dl, p>0.05). Patients older than 80 yrs. had a significant longer catheterization time (mean 2.47 days) compared to patients aged 70e79 yrs (mean 2.25 days, p<0.03) and patients aged 60e69 yrs. (mean 2.16 days, p<0.016), respectively. Median postoperative PVR, Qmax, IPSS, and QoL were 25 ml, 17.95 ml/s, 4, and 1 at 12-month follow-up and significantly improved compared to preoperative assessment (p<0.001) but without differences among the age groups (p>0.05). CONCLUSIONS: Overall morbidity, and 12-month functional outcome of ThuVEP were similar among all age groups. ThuVEP is a safe and effective procedure for the treatment of symptomatic BPO regardless of age. Source of Funding: None.
MP13-13 FUNCTIONAL RESULTS AFTER PHOTOVAPORISATION OF THE PROSTATE (PVP) WITH GREENLIGHT XPS LASER: A PROSPECTIVE MULTI-INSTITUTIONAL STUDY. Maxime Thoulouzan*, Romain Huet, Romain Mathieu, Karim Bensalah, Rennes, France; Jehanne Calves, Brest, France; Pierre Coeurdacier, vigne , France; Luc Corbel, Emmanuel Della Negra, Cesson-Se Saint-Brieuc, France; Alexandre Fourcade, Brest, France; Benoit Gires, e Perrouin-Verbe, Vivien Grafeille, Rennes, France; Marie-Aime gory Verhoest, Sophie Serey-Eiffel, Antoine Valeri, Brest, France; Gre bastien Vincendeau, Rennes, France; Georges Fournier, Brest, Se France INTRODUCTION AND OBJECTIVES: PVP with Greenlight laser is an alternative to monopolar trans-urethral resection of the prostate (TURP). Since 2010, Greenlight XPS with the new MoXy fibre is the latest technological evolution. We report the short-term and midterm functional results of a large prospective and multi-institutional cohort. METHODS: From September 2010 to April 2014, 575 patients with symptomatic benign prostatic hyperplasia (BPH) underwent PVP with Greenlight XPS laser. Surgery was performed by 20 different surgeons in 4 institutions. Baseline characteristics and perioperative data were assessed prospectively. Functional results (IPSS and IIEF5 scores, maximum flow rate (Qmax) and post-void residual (PVR)) were evaluated at 1 or 3 months, and 12 months postoperatively. RESULTS: Mean patient age was 698 years, PSA was 5.76.6 ng/ml and prostate volume was 6436 ml. 26% of patients were in urinary retention. 41% were on antiplatelet therapy and 8% on anticoagulants. Mean operative time was 7835 min, and mean energy delivered was 306195 kJ (4,8 kJ/ml). At 1/3 and 12 months follow-up, there was a significant improvement of IPSS, quality of life, Qmax and PVR (table and figure 1). There was no impact on erectile function. Among patients with preoperative urinary catheter, 88% were discharged catheter free postoperatively, with mean Qmax, PVR and IPSS of 19 ml/s, 32 ml, and 5.7 at 1/3 months follow-up, and of 19 ml/s, 28 ml et 6.0 at 12 months follow-up, respectively. CONCLUSIONS: PVP with Greenlight XPS laser for the treatment of symptomatic BPH is safe and efficient. In our multi-institutional experience, functional results are reproducible and stable at one-year follow-up.
Source of Funding: none
MP13-14 180W LBO LASER VAPORIZATION OF THE PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA IN HIGH-RISK PATIENTS Pierre-Alain Hueber*, Marc Nicolas Bienz, Roger Valdivieso, Hugo Lavigueur-Blouin, Montreal, Canada; Vincent Misrai, Toulouse, France; Matthew Rutman, Alexis Te, Bilal Chughtai, New York, NY; Neil Barber, Amr Emara, Frimley, Surrey, United Kingdom; Ravi Munver, Hackensack, NJ; Naeem Bhojani, Kevin Zorn, Montreal, Canada INTRODUCTION AND OBJECTIVES: The aim of this study is to evaluate the surgical performance, complication rates and outcomes up to 2 years of the Greenlight XPS-180W laser system (AMS, Minnetonka, MI, USA) for the treatment of BPH in high-risk patients from a large international multicenter cohort. The current analysis focuses on the subgroups of patients on anticoagulant (ACO) therapy, of older age80 (Age80), very large prostate 120cc (PV120) or with indwelling catheter for urinary retention. METHODS: A total of 1194 patients underwent Greenlight laser photo-selective vaporization of the prostate for the treatment of BPH performed at 6 international centers. Preoperative data including the use of anticoagulant were recorded. Operative parameters, complications as well as outcomes at 3, 6 12, 18 and 24 months postoperatively
Vol. 193, No. 4S, Supplement, Friday, May 15, 2015
e141
was 50 ml in each age group and not different among them (p>0.05). The overall morbidity rates were similar among the age groups (28.3%, 36.6%, 32.9%, p>0.05), as were the incidence of significant complications (Clavien two or larger) and median loss of haemoglobin (1.1 g/dl, p>0.05). Patients older than 80 yrs. had a significant longer catheterization time (mean 2.47 days) compared to patients aged 70e79 yrs (mean 2.25 days, p<0.03) and patients aged 60e69 yrs. (mean 2.16 days, p<0.016), respectively. Median postoperative PVR, Qmax, IPSS, and QoL were 25 ml, 17.95 ml/s, 4, and 1 at 12-month follow-up and significantly improved compared to preoperative assessment (p<0.001) but without differences among the age groups (p>0.05). CONCLUSIONS: Overall morbidity, and 12-month functional outcome of ThuVEP were similar among all age groups. ThuVEP is a safe and effective procedure for the treatment of symptomatic BPO regardless of age. Source of Funding: None.
MP13-13 FUNCTIONAL RESULTS AFTER PHOTOVAPORISATION OF THE PROSTATE (PVP) WITH GREENLIGHT XPS LASER: A PROSPECTIVE MULTI-INSTITUTIONAL STUDY. Maxime Thoulouzan*, Romain Huet, Romain Mathieu, Karim Bensalah, Rennes, France; Jehanne Calves, Brest, France; Pierre Coeurdacier, vigne , France; Luc Corbel, Emmanuel Della Negra, Cesson-Se Saint-Brieuc, France; Alexandre Fourcade, Brest, France; Benoit Gires, e Perrouin-Verbe, Vivien Grafeille, Rennes, France; Marie-Aime gory Verhoest, Sophie Serey-Eiffel, Antoine Valeri, Brest, France; Gre bastien Vincendeau, Rennes, France; Georges Fournier, Brest, Se France INTRODUCTION AND OBJECTIVES: PVP with Greenlight laser is an alternative to monopolar trans-urethral resection of the prostate (TURP). Since 2010, Greenlight XPS with the new MoXy fibre is the latest technological evolution. We report the short-term and midterm functional results of a large prospective and multi-institutional cohort. METHODS: From September 2010 to April 2014, 575 patients with symptomatic benign prostatic hyperplasia (BPH) underwent PVP with Greenlight XPS laser. Surgery was performed by 20 different surgeons in 4 institutions. Baseline characteristics and perioperative data were assessed prospectively. Functional results (IPSS and IIEF5 scores, maximum flow rate (Qmax) and post-void residual (PVR)) were evaluated at 1 or 3 months, and 12 months postoperatively. RESULTS: Mean patient age was 698 years, PSA was 5.76.6 ng/ml and prostate volume was 6436 ml. 26% of patients were in urinary retention. 41% were on antiplatelet therapy and 8% on anticoagulants. Mean operative time was 7835 min, and mean energy delivered was 306195 kJ (4,8 kJ/ml). At 1/3 and 12 months follow-up, there was a significant improvement of IPSS, quality of life, Qmax and PVR (table and figure 1). There was no impact on erectile function. Among patients with preoperative urinary catheter, 88% were discharged catheter free postoperatively, with mean Qmax, PVR and IPSS of 19 ml/s, 32 ml, and 5.7 at 1/3 months follow-up, and of 19 ml/s, 28 ml et 6.0 at 12 months follow-up, respectively. CONCLUSIONS: PVP with Greenlight XPS laser for the treatment of symptomatic BPH is safe and efficient. In our multi-institutional experience, functional results are reproducible and stable at one-year follow-up.
Source of Funding: none
MP13-14 180W LBO LASER VAPORIZATION OF THE PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA IN HIGH-RISK PATIENTS Pierre-Alain Hueber*, Marc Nicolas Bienz, Roger Valdivieso, Hugo Lavigueur-Blouin, Montreal, Canada; Vincent Misrai, Toulouse, France; Matthew Rutman, Alexis Te, Bilal Chughtai, New York, NY; Neil Barber, Amr Emara, Frimley, Surrey, United Kingdom; Ravi Munver, Hackensack, NJ; Naeem Bhojani, Kevin Zorn, Montreal, Canada INTRODUCTION AND OBJECTIVES: The aim of this study is to evaluate the surgical performance, complication rates and outcomes up to 2 years of the Greenlight XPS-180W laser system (AMS, Minnetonka, MI, USA) for the treatment of BPH in high-risk patients from a large international multicenter cohort. The current analysis focuses on the subgroups of patients on anticoagulant (ACO) therapy, of older age80 (Age80), very large prostate 120cc (PV120) or with indwelling catheter for urinary retention. METHODS: A total of 1194 patients underwent Greenlight laser photo-selective vaporization of the prostate for the treatment of BPH performed at 6 international centers. Preoperative data including the use of anticoagulant were recorded. Operative parameters, complications as well as outcomes at 3, 6 12, 18 and 24 months postoperatively